The GSP Crop Science IPO enters its second day of subscription today, 17 March 2026. By the end of the first day, the issue was subscribed to 0.48 times overall. The bidding window is scheduled to close on March 18, 2026.
Issue Type: The GSP Crop Science IPO is a book-build issue of ₹400 crore, consisting of a fresh issue of ₹250 crore and an offer for sale (OFS) of ₹160 crore.
Price Band: The price band is set between ₹304 and ₹320 per share.
Lot Size & Minimum Investment: The lot size for an application is 46 shares, and the minimum investment required is ₹14,720 (for retail investors).
Allotment Date: The basis of allotment will be finalised by March 20, 2026
Listing Date: The tentative listing date on NSE and BSE is March 24, 2026.
Book-running Lead Managers: Equirus Capital Private Limited and Motilal Oswal Investment Advisors Limited
Registrar: MUFG Intime India Private Limited
[17-March-2026 10:57:00 hrs]
|
Investor Category |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
1.28 |
|
Non-Institutional Investors |
0.86 |
|
Retail Individual Investors (RIIs) |
0.14 |
|
Total |
0.61 |
The net proceeds from the fresh issue will be used to fund the expenses towards the following objectives:
Explore other Upcoming IPOs on BSE and NSE.
According to media reports, the Grey Market Premium (GMP) of the GSP Crop Science IPO is reported at ₹0 over the IPO price.
GSP Crop Science is an agrochemical company with over four decades of industry experience in India. Their core operations revolve around the development, manufacturing, and commercialisation of crop protection products, including insecticides, herbicides, fungicides, and plant growth regulators. The company delivers effective solutions that help farmers enhance crop yield and improve agricultural productivity.
As of September 30, 2025, the company has secured 524 product registrations across formulations and technical portfolios, granted 102 patents to date and has 108 additional patent applications under review.
Check out newly Listed IPOs on BSE and NSE.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.